Novel 5‑[2,7-Diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione Derivatives as MMP9 Inhibitors for Treating Ocular Surface Diseases, in Particular Dry Eye Disease

Provided herein are novel 5-[2,7-diazaspiro[3.5]-nonan-7-yl]-5-[4-phenoxyphenyl]-hexahydropyrimidine-2,4,6-trione derivatives as MMP9 inhibitors, pharmaceutical compositions, use of such compounds in treating ocular surface diseases, in particular dry eye disease, and processes for preparing such compounds.